Diagnostic Center | June 04, 2025
iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure